Targeting enzyme inhibitors in drug discovery

Author： Copeland Robert A Harpel Mark R Tummino Peter J

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.11, Iss.7, 2007-07, pp. : 967-978

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Review of: “Evaluation of Enzyme Inhibitors in Drug Discovery”

By Woster Patrick

Drug Development and Industrial Pharmacy, Vol. 32, Iss. 3, 2006-04 ,pp. : 399-400

Informa Healthcare

Access to resources Recommend Favorite

Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants

Current Cancer Drug Targets, Vol. 17, Iss. 7, 2017-08 ,pp. : 617-636

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 8, 2010-06 ,pp. : 828-858

Bentham Science Publishers

Access to resources Recommend Favorite

New directions in drug discovery: targeting RNA

Inpharma, Vol. 1, Iss. 1386, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Antiviral Drug Discovery Targeting to Viral Proteases

Current Pharmaceutical Design, Vol. 12, Iss. 11, 2006-04 ,pp. : 1301-1314

Bentham Science Publishers

Access to resources Recommend Favorite